Avedro Financing Highlights New Ophthalmology Market
This article was originally published in Start Up
In early July, ophthalmology start-up Avedro closed a $25 million Series C round. In a refractive surgery market where, apart from laser cataract surgery, there hasn't been much new to speak of in years, Avedro has a potentially disruptive technology, although the company plans not to disrupt as much as to grow the market.
You may also be interested in...
Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.
Among new technologies discussed at three major ophthalmology conferences this fall, it was the emerging field of laser cataract surgery that generated the greatest interest among attendees, although the first system is just now being launched commercially and there are many unanswered questions regarding the economics of this promising technology and how it will be adopted.
At this year's American Society of Cataract and Refractive Surgery symposium, enthusiasm over technological advances in nearly every product segment, including presbyopia-correcting IOLs and cataract surgeries, was dampened by the reality of the softening demand for laser vision correction.